Skip to main content

Table 2 Resistance to each NRTI among patients failing first-line antiretroviral therapy

From: HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon

 

Group-A: AZT and D4T n = 55

HIVDR

High (%)

Intermediate (%)

Susceptible (%)

3TC

45 (81.8%)

0 (0.0%)

10 (18.2%)

ABC

11 (20.0%)

19 (34.5%)

25 (45.5%)

AZT

23 (41.8%)

8 (14.6%)

24 (43.6%)

D4T

23 (41.8%)

7 (12.7%)

25 (45.5%)

DDI

14 (25.4%)

11 (20.0%)

30 (54.6%)

FTC

45 (81.8%)

0 (0.0%)

10 (18.2%)

TDF

3 (5.5%)

13 (23.6%)

39 (70.9%)

 

Group-B: TDF + D4T or AZT n = 22

HIVDR

High (%)

Intermediate (%)

Susceptible (%)

3TC

19 (86.4%)

0 (0.0%)

3 (13.6%)

ABC

10 (45.5%)

6 (27.3%)

6 (27.3%)

AZT

3 (13.6%)

5 (22.7%)

14 (63.6%)

D4T

4 (18.2%)

9 (40.9%)

9 (40.9%)

DDI

10 (45.5%)

2 (9.1%)

5 (45.5%)

FTC

19 (86.4%)

0 (0.0%)

3 (13.6%)

TDF

6 (27.3%)

1 (4.5%)

15 (68.2%)

 

Group-C: D4T (i.e. Triomune) n = 24

HIVDR

High (%)

Intermediate (%)

Susceptible (%)

3TC

20 (83.3%)

0 (0.0%)

4 (16.7%)

ABC

7 (29.2%)

8 (33.3%)

9 (37.5%)

AZT

10 (41.7%)

5 (20.8%)

9 (37.5%)

D4T

10 (41.6%)

5 (20.8%)

9 (37.5%)

DDI

8 (33.3%)

4 (16.7%)

12 (50.0%)

FTC

20 (83.3%)

0 (0.0%)

4 (16.7%)

TDF

2 (8.3%)

2 (8.3%)

20 (83.3%)

  1. Legend. HIVDR HIV drug resistance, 3TC Lamivudine, ABC Abacavir, AZT Zidovudine, D4T Stavudine, DDI Didanosine, FTC Emtricitabine, TDF Tenofovir, Triomune D4T + 3TC + Nevirapine. Footnote: Prior exposure to D4T and AZT was not concomitant